Aptevo Therapeutics Inc.
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 15.17% | -52.22% | -302.94% | -102.67% | -103.55% |
| Gross Profit | -15.17% | 52.22% | 302.94% | 102.67% | 103.55% |
| SG&A Expenses | 12.34% | -6.52% | -13.79% | -13.14% | -12.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.51% | -6.36% | -14.26% | -14.81% | -18.47% |
| Operating Income | -8.51% | 6.36% | 14.26% | 14.81% | 18.47% |
| Income Before Tax | -10.24% | 4.84% | 13.21% | -29.38% | -36.30% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.24% | 4.84% | 13.21% | -29.38% | -36.30% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -80.03% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.60% | 3.72% | 12.27% | -38.58% | -46.87% |
| EBIT | -8.51% | 6.36% | 14.26% | 14.81% | 18.47% |
| EBITDA | -9.34% | 5.80% | 13.83% | 14.35% | 18.13% |
| EPS Basic | 29.26% | -- | -- | -- | -- |
| Normalized Basic EPS | 29.36% | -- | -- | -- | -- |
| EPS Diluted | 29.21% | -- | -- | -- | -- |
| Normalized Diluted EPS | 29.36% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 34,171.33% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 34,171.33% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |